DARZALEX® + Rd dosing



DARZALEX® + Revlimid® (lenalidomide) + dexamethasone

DARZALEX® dosing frequency decreases throughout the course of therapy1

  • DARZALEX® is given as an intravenous (IV) infusion after dilution at 16 mg/kg of actual body weight
  • Lenalidomide is given orally on days 1–21 of each cycle*
  • Dexamethasone is given orally or IV once a week
    • On DARZALEX® infusion days, 20 mg of the dexamethasone dose was given as a pre-infusion medication and the remainder given the day after the infusion

Want a PDF of the DARZALEX® + Rd dosing schedule?

Looking for a comprehensive guide with DARZALEX® dosing & administration?

  • DARZALEX® should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions if they occur1
  • If a planned dose of DARZALEX® is missed, administer the dose as soon as possible and adjust the dosing schedule accordingly, maintaining the treatment interval1

Interference with Serological Testing

  • Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test)
  • Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion
  • Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum. The determination of a patient’s ABO and Rh blood type is not impacted
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®
  • Type and screen patients prior to starting DARZALEX®

Find out more about interference with serological testing for patients being treated with DARZALEX®

Provide this document to patients to let healthcare professionals know that the patient is being treated with DARZALEX®